Thirumalai Chemicals Reports Significant FY26 Losses Amid Revenue Decline

Consolidated Loss FY26: ₹-167.91 crore | Consolidated Revenue FY26: ₹1,735.52 crore

Reader Takeaway: Challenging FY26 results with widened losses and revenue drop; focus on securing subsidiary funding.

What just happened

Thirumalai Chemicals Limited has announced its audited financial results for the fiscal year ended March 31, 2026. The company reported a substantial increase in consolidated losses to ₹167.91 crore, a significant jump from ₹46.10 crore in the previous fiscal year. Standalone losses also shifted from a profit of ₹82.21 crore in FY25 to a loss of ₹65.40 crore in FY26.

Consolidated revenue from operations decreased by approximately 15.3% to ₹1,735.52 crore in FY26, down from ₹2,049.51 crore in FY25. On a standalone basis, revenue saw a sharper decline of about 36.8%, falling to ₹1,359.73 crore from ₹2,152.07 crore.

The company also recorded impairment losses related to non-operational plants, amounting to ₹4.44 crore standalone and ₹7.98 crore consolidated.

Why this matters

These results highlight a difficult operational year for Thirumalai Chemicals. The widening losses and contracting revenues signal profitability challenges. Furthermore, the company is experiencing significant working capital pressure, with current liabilities exceeding current assets on both standalone and consolidated bases. Negative operating cash flows of ₹130.73 crore for the group add to liquidity concerns.

The backstory

In the previous fiscal year (FY25), Thirumalai Chemicals had reported a consolidated profit of ₹-46.10 crore. The current year's performance marks a substantial deterioration. The company's efforts to secure funding for subsidiary construction activities are a key ongoing development.

What changes now

Management remains confident in the company's ability to operate on a 'going concern' basis, citing revolving credit facilities and debt funding plans. A critical development is the subsidiary TCL Specialties LLC, USA, being in advanced stages of securing a USD 130 million term loan facility. This funding is crucial for supporting ongoing plant construction.

Risks to watch

The primary risks revolve around the company's liquidity position and its ability to manage working capital effectively. The successful procurement of the USD 130 million debt facility for the US subsidiary is paramount. Additionally, improving operating cash flows will be vital for long-term stability.

Peer comparison

While specific peer financial data is not provided in the filing, the reported revenue contraction and increased losses suggest Thirumalai Chemicals is facing industry-wide or company-specific headwinds that may also be affecting its competitors in the chemical sector.

Context metrics (time-bound)

• FY26 Consolidated Revenue: ₹1,735.52 crore (down 15.3% from FY25)
• FY26 Consolidated Loss: ₹-167.91 crore (vs. ₹-46.10 crore in FY25)
• FY26 Standalone Revenue: ₹1,359.73 crore (down 36.8% from FY25)
• FY26 Standalone Loss: ₹-65.40 crore (vs. ₹82.21 crore profit in FY25)
• Group Operating Cash Flow FY26: ₹-130.73 crore

What to track next

Investors will be closely monitoring the progress of the USD 130 million debt facility for TCL Specialties LLC, USA. The company's ability to stabilize its revenue and cash flows in the upcoming financial periods will also be crucial indicators of its financial health.